Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ARE NYSE:BXP NYSE:CUZ NASDAQ:MRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAREAlexandria Real Estate Equities$48.36+1.1%$46.12$39.41▼$88.24$8.43B1.122.38 million shs1.39 million shsBXPBXP$60.32+0.3%$55.69$49.72▼$79.33$9.61B1.041.70 million shs1.06 million shsCUZCousins Properties$26.52+0.4%$24.08$21.03▼$30.81$4.36B1.212.16 million shs1.26 million shsMRNAModerna$46.88-0.8%$50.82$22.28▼$59.55$18.60B1.058.07 million shs4.22 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAREAlexandria Real Estate Equities0.00%+7.63%+4.18%-9.88%-29.50%BXPBXP0.00%+3.15%+5.88%-0.91%-7.23%CUZCousins Properties0.00%+2.75%+7.84%+10.78%-1.59%MRNAModerna0.00%-4.40%-11.30%-6.00%+81.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAREAlexandria Real Estate Equities$48.36+1.1%$46.12$39.41▼$88.24$8.43B1.122.38 million shs1.39 million shsBXPBXP$60.32+0.3%$55.69$49.72▼$79.33$9.61B1.041.70 million shs1.06 million shsCUZCousins Properties$26.52+0.4%$24.08$21.03▼$30.81$4.36B1.212.16 million shs1.26 million shsMRNAModerna$46.88-0.8%$50.82$22.28▼$59.55$18.60B1.058.07 million shs4.22 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAREAlexandria Real Estate Equities0.00%+7.63%+4.18%-9.88%-29.50%BXPBXP0.00%+3.15%+5.88%-0.91%-7.23%CUZCousins Properties0.00%+2.75%+7.84%+10.78%-1.59%MRNAModerna0.00%-4.40%-11.30%-6.00%+81.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAREAlexandria Real Estate Equities 2.06Hold$51.316.11% UpsideBXPBXP 2.48Hold$71.6018.70% UpsideCUZCousins Properties 2.56Moderate Buy$28.366.97% UpsideMRNAModerna 1.84Reduce$35.73-23.78% DownsideCurrent Analyst Ratings BreakdownLatest ARE, MRNA, BXP, and CUZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026AREAlexandria Real Estate Equities The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$52.005/18/2026BXPBXP BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$66.00 ➝ $65.005/15/2026CUZCousins Properties Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/15/2026BXPBXP Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$79.00 ➝ $70.005/14/2026BXPBXP UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$66.00 ➝ $61.005/13/2026BXPBXP Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$61.005/13/2026BXPBXP Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold$81.005/5/2026AREAlexandria Real Estate Equities Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$60.00 ➝ $50.005/4/2026MRNAModerna UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$36.00 ➝ $45.005/4/2026MRNAModerna Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$35.00 ➝ $38.005/4/2026AREAlexandria Real Estate Equities EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAREAlexandria Real Estate Equities$3.03B2.78N/AN/A$111.06 per share0.44BXPBXP$3.48B2.76$8.17 per share7.38$48.40 per share1.25CUZCousins Properties$1.01B4.33$2.74 per share9.67$27.55 per share0.96MRNAModerna$1.94B9.57N/AN/A$18.67 per share2.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAREAlexandria Real Estate Equities-$1.43B-$6.27N/A8.155.86-36.03%-5.21%-2.96%7/20/2026 (Estimated)BXPBXP$276.80M$1.9930.318.382.609.09%4.13%1.23%8/4/2026 (Estimated)CUZCousins Properties$40.50M-$0.03N/A8.691.96-0.52%-0.11%-0.06%7/30/2026 (Estimated)MRNAModerna-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)Latest ARE, MRNA, BXP, and CUZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2026Q1 2026MRNAModerna-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million4/29/2026Q1 2026CUZCousins Properties$0.0605-$0.15-$0.2105-$0.15$256.77 million$263.11 million4/28/2026Q1 2026BXPBXP$1.58$0.64-$0.94$0.64$843.11 million$872.15 million4/27/2026Q1 2026AREAlexandria Real Estate Equities$1.73$1.73N/A$2.10$684.78 million$671.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAREAlexandria Real Estate Equities$2.885.96%+1.99%N/A 15 YearsBXPBXP$2.804.64%-3.04%140.70%N/ACUZCousins Properties$1.284.83%-2.99%N/A N/AMRNAModernaN/AN/AN/AN/AN/ALatest ARE, MRNA, BXP, and CUZ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/18/2026BXPBXPquarterly$0.705.4%3/31/20263/31/20264/30/20262/27/2026AREAlexandria Real Estate Equitiesquarterly$0.726.21%3/31/20263/31/20264/15/20263/18/2026CUZCousins Propertiesquarterly$0.325.77%4/7/20264/7/20264/15/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAREAlexandria Real Estate Equities0.650.200.20BXPBXP2.074.224.22CUZCousins Properties0.831.211.21MRNAModerna0.082.412.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAREAlexandria Real Estate Equities96.54%BXPBXP98.72%CUZCousins Properties94.38%MRNAModerna75.33%Insider OwnershipCompanyInsider OwnershipAREAlexandria Real Estate Equities1.35%BXPBXP1.50%CUZCousins Properties1.81%MRNAModerna10.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAREAlexandria Real Estate Equities590174.27 million171.92 millionOptionableBXPBXP780159.48 million157.09 millionOptionableCUZCousins Properties256,131164.54 million161.56 millionOptionableMRNAModerna4,700396.79 million353.93 millionOptionableARE, MRNA, BXP, and CUZ HeadlinesRecent News About These CompaniesModerna’s mRNA flu shot to get FDA reviewMay 24 at 8:24 AM | thehill.comTNoubar Afeyan Sells 9,263 Shares of Moderna (NASDAQ:MRNA) StockMay 24 at 4:57 AM | americanbankingnews.comModerna (NASDAQ:MRNA) Director Sells $433,878.92 in StockMay 23 at 8:24 AM | insidertrades.comInsider Selling: Moderna (NASDAQ:MRNA) Director Sells $433,878.92 in StockMay 22 at 7:12 PM | marketbeat.comUSFDA to Convene Expert Panel Review for Moderna's mRNA Flu VaccineMay 22 at 2:58 PM | medicaldialogues.inMFDA plans rare advisory hearing to debate Moderna’s flu shotMay 22 at 9:57 AM | msn.comJames Mock Joins Moderna as Chief Financial OfficerMay 22 at 9:57 AM | finance.yahoo.comModerna mRNA flu vaccine to get FDA panel reviewMay 22 at 9:57 AM | yahoo.comModerna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's ChangedMay 22 at 9:57 AM | finance.yahoo.comModerna, Inc. (NASDAQ:MRNA) Receives Average Rating of "Reduce" from AnalystsMay 22 at 2:48 AM | americanbankingnews.comMRNA Stock Slips: FDA Slates Advisory Hearing On Experimental Flu ShotMay 21 at 6:19 PM | stocktwits.comSModerna, Merck cancer combo cuts melanoma spread risk at five yearsMay 21 at 5:03 PM | reuters.comUS FDA to hold expert committee meeting to review Moderna's flu vaccineMay 21 at 1:19 PM | msn.comModerna to face FDA AdCom review for flu shotMay 21 at 1:19 PM | msn.comForget Moderna: This Biotech Juggernaut Is a Way Better Buy Right NowMay 21 at 9:36 AM | 247wallst.comPfizer, Moderna COVID vaccines 70% to 76% effective against severe illness in kids in 2022, data suggestMay 19, 2026 | cidrap.umn.eduCHHS cancels funding for Moderna vaccines to fight pandemic fluMay 19, 2026 | msn.comModerna, Inc. (MRNA) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19, 2026 | seekingalpha.comModerna (NASDAQ:MRNA) President Stephen Hoge Sells 53,336 SharesMay 19, 2026 | insidertrades.comModerna Reports Second Quarter 2025 Financial Results and Provides Business UpdatesMay 18, 2026 | freep.comFModerna Reports Third Quarter 2025 Financial Results and Provides Business UpdatesMay 17, 2026 | freep.comFNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIndustrial Chips Are in Rally Mode—5 Ways to PlayBy Thomas Hughes | April 27, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Roblox Stock Slides to New Low as Safety Changes Weigh on OutlookBy Jennifer Ryan Woods | May 3, 2026Why Applied Optoelectronics Stock May Be Near a Turning PointBy Thomas Hughes | May 18, 2026Robinhood, SoFi, and Webull Are Telling Very Different StoriesBy Peter Frank | May 17, 2026ARE, MRNA, BXP, and CUZ Company DescriptionsAlexandria Real Estate Equities NYSE:ARE$48.36 +0.51 (+1.06%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$47.82 -0.53 (-1.10%) As of 05/22/2026 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science, agtech, and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a total market capitalization of $33.1 billion and an asset base in North America of 73.5 million SF as of December 31, 2023, which includes 42.0 million RSF of operating properties, 5.5 million RSF of Class A/A+ properties undergoing construction and one near-term project expected to commence construction in the next two years, 2.1 million RSF of priority anticipated development and redevelopment projects, and 23.9 million SF of future development projects. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science, agtech, and advanced technology mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science, agrifoodtech, climate innovation, and technology companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.BXP NYSE:BXP$60.32 +0.19 (+0.32%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$60.24 -0.08 (-0.14%) As of 05/22/2026 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Boston Properties, Inc. (NYSE: BXP) (BXP or the Company) is the largest publicly traded developer, owner, and manager of premier workplaces in the United States, concentrated in six dynamic gateway markets - Boston, Los Angeles, New York, San Francisco, Seattle, and Washington, DC. BXP has delivered places that power progress for our clients and communities for more than 50 years. BXP is a fully integrated real estate company, organized as a real estate investment trust (REIT). Including properties owned by joint ventures, BXP's portfolio totals 53.3 million square feet and 188 properties, including 10 properties under construction/redevelopment. BXP's properties include 167 office properties, 14 retail properties (including two retail properties under construction/redevelopment), six residential properties (including one residential property under construction) and one hotel. BXP is well-known for its inhouse building management expertise and responsiveness to clients' needs. BXP holds a superior track record of developing premium Central Business District (CBD) office buildings, successful mixed-use complexes, suburban office centers and build-to-suit projects for a diverse array of creditworthy clients. BXP actively works to promote its growth and operations in a sustainable and responsible manner. BXP has earned a twelfth consecutive GRESB Green Star recognition and the highest GRESB 5-star Rating. BXP, an S&P 500 company, was founded in 1970 by Mortimer B. Zuckerman and Edward H. Linde and became a public company in 1997.Cousins Properties NYSE:CUZ$26.52 +0.10 (+0.36%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$26.50 -0.01 (-0.04%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cousins Properties Incorporated ("Cousins") is a fully integrated, self-administered, and self-managed real estate investment trust (REIT). The Company, based in Atlanta and acting through its operating partnership, Cousins Properties LP, primarily invests in Class A office buildings located in high-growth Sun Belt markets. Founded in 1958, Cousins creates shareholder value through its extensive expertise in the development, acquisition, leasing, and management of high-quality real estate assets. The Company has a comprehensive strategy in place based on a simple platform, trophy assets, and opportunistic investments.Moderna NASDAQ:MRNA$46.88 -0.38 (-0.80%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$46.89 +0.01 (+0.02%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
